Glaukos announces positive three-year Epioxa Phase 3 extension results
Glaukos said topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating Epioxa in keratoconus showed positive three-year outcomes, described as durable.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.